The incorporation of Ang-2 in the diagnosis of stage IIIβ NSCLC could significantly improve the precise prognosis of lung cancer, while Ang-2 blockade could serve as a potential future therapeutic approach for lung cancer. Here, ANGPT2 is linked to lung carcinoma.